From drug discovery to biomarker-driven clinical trials in lymphoma

Nature Reviews Clinical Oncology

Volumn 9, Issue 11, 2012, Pages 643-653

  Younes, Anas ^a   Berry, Donald A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; BRENTUXIMAB VEDOTIN; CETUXIMAB; CRIZOTINIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPRATUZUMAB; ERLOTINIB; EVEROLIMUS; FOSTAMATINIB; GEFITINIB; IDELALISIB; IMATINIB; INOTUZUMAB OZOGAMICIN; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISOLONE; PROTEIN KINASE B; RITUXIMAB; STAT3 PROTEIN; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; TUMOR MARKER; UNINDEXED DRUG; VEMURAFENIB; VINCRISTINE;

B CELL LYMPHOMA; BREAST CANCER; CANCER CLASSIFICATION; CANCER GENETICS; CANCER PATIENT; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COLORECTAL CARCINOMA; DIAGNOSTIC ERROR; DRUG APPROVAL; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; FOLLICULAR LYMPHOMA; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC DISORDER; GENETIC SCREENING; GENOMICS; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LARGE CELL LYMPHOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MANTLE CELL LYMPHOMA; MELANOMA; METHODOLOGY; MOLECULAR GENETICS; NONHODGKIN LYMPHOMA; NONHUMAN; PATIENT SELECTION; PERIPHERAL T CELL LYMPHOMA; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; LYMPHOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84868201754     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.156     Document Type: Review

References (94)

1. Younes, A. Beyond chemotherapy: New agents for targeted treatment of lymphoma. Nat. Rev. Clin. Oncol. 8, 85-96 (2011
2. Friedberg, J. W. New strategies in diffuse large B cell lymphoma: Translating findings from gene expression analyses into clinical practice. Clin. Cancer Res. 17, 6112-6117 (2011
3. Hagberg, H. & Gisselbrecht, C. Randomised phase III study of RICE versus R DHAP in relapsed patients with CD20 diffuse large B cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: An update of the CORAL study. Ann. Oncol. 7 (Suppl. 4), iv31-iv32 (2006
4. Younes, A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology Am. Soc. Hematol. Educ. Program 2009, 507-519 (2009
5. Chen, W. L. et al. The clinicopathological analysis of 303 cases with malignant lymphoma classified according to the World Health Organization classification system in a single institute of Taiwan. Ann. Hematol. 89, 553-562 (2010
6. Good, D. J. & Gascoyne, R. D. Classification of non-Hodgkin's lymphoma. Hematol. Oncol. Clin. North Am. 22, 781-805 (2008
7. Tan, L. H. A practical approach to the understanding and diagnosis of lymphoma: An assessment of the WHO classification based on immunoarchitecture and immuno-ontogenic principles. Pathology 41, 305-326 (2009
8. LoRusso, P. M., Boerner, S. A. & Seymour, L. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. Clin. Cancer Res. 16, 1710-1718 (2010
9. Ledford, H. Translational research: 4 ways to fix the clinical trial. Nature 477, 526-528 (2011
10. Robertson, M. J. et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B cell lymphoma. J. Clin. Oncol. 25, 1741-1746 (2007
11. Advani, R. et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J. Clin. Oncol. 27, 4371-4377 (2009
12. Younes, A. et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: An open-label, single-arm, phase 2 trial. Lancet Oncol. 12, 1222-1228 (2011
13. Friedberg, J. W. et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115, 2578-2585 (2010
14. Arrowsmith, J. Trial watch: phase III and submission failures: 2007-2010. Nat. Rev. Drug Discov. 10, 87 (2011
15. Alizadeh, A. A. et al. Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature 403, 503-511 (2000
16. Hess, G. et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 27, 3822-3829 (2009
17. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646-674 (2011
18. Chin, L., Andersen, J. N. & Futreal, P. A. Cancer genomics: From discovery science to personalized medicine. Nat. Med. 17, 297-303 (2011
19. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011
20. Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non small cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010
21. Pasqualucci, L. et al. Analysis of the coding genome of diffuse large B cell lymphoma. Nat. Genet. 43, 830-837 (2011
22. Morin, R. D. et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298-303 (2011
23. Cairns, R. A. et al. IDH2 mutations are frequent in angioimmunoblastic T cell lymphoma. Blood 119, 1901-1903 (2012
24. Kridel, R. et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 119, 1963-1971 (2012
25. Lohr, J. G. et al. Discovery and prioritization of somatic mutations in diffuse large B cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl Acad. Sci. USA 109, 3879-3884 (2012
26. Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514-523 (2011
27. Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449-456 (2008
28. Johnston, P. B. et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am. J. Hematol. 85, 320-324 (2010
29. Witzig, T. E. et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 25, 341-347 (2011
30. Witzig, T. E. et al. Phase II trial of single-agent temsirolimus (CCI 779) for relapsed mantle cell lymphoma. J. Clin. Oncol. 23, 5347-5356 (2005
31. Smith, S. M. et al. Activity of single agent temsirolimus (CCI 779) in non-mantle cell non-Hodgkin lymphoma subtypes [abstract]. J. Clin. Oncol. 26 (Suppl.), a8514 (2008
32. Kahl, B. et al. Significant clinical activity of cal 101, an isoform-selective inhibitor of phosphatidylinositol 3 kinase p110d, in patients with relapsed or refractory indolent and mantle cell lymphoma [abstract]. Ann. Oncol. 22, 199 (2011
33. Fowler, N. et al. A phase I trial of Btk inhibitor PCI 32765 in patients with relapsed non-Hodgkin's lymphoma: Evidence of antitumor activity [abstract]. Haematologica 95, 371 (2010
34. Younes, A. & Samad, N. Utility of mTOR inhibition in hematologic malignancies. Oncologist 16, 730-741 (2011
35. Wang, L. H. et al. The Bruton's tyrosine kinase inhibitor PCI 32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial [abstract]. Blood 118, 203-204 (2011
36. Iqbal, J. et al. BCL2 expression is a prognostic marker for the activated B cell like type of diffuse large B cell lymphoma. J. Clin. Oncol. 24, 961-968 (2006
37. Casasnovas, R. O. et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: A study from the Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. 25, 1732-1740 (2007
38. de Jong, D. et al. Immunohistochemical prognostic markers in diffuse large B cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications- a study from the Lunenburg Lymphoma Biomarker Consortium. J. Clin. Oncol. 25, 805-812 (2007
39. Korenberg, M. J., Farinha, P. & Gascoyne, R. D. Predicting survival in follicular lymphoma using tissue microarrays. Methods Mol. Biol. 377, 255-268 (2007
40. Halait, H. et al. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagn. Mol. Pathol. 21, 1-8 (2012
41. Shaw, A. T., Solomon, B. & Kenudson, M. M. Crizotinib and testing for ALK. J. Natl Compr. Canc. Netw. 9, 1335-1341 (2011
42. Liotta, L. A. & Petricoin, E. Cancer biomarkers: Closer to delivering on their promise. Cancer Cell 20, 279-280 (2011
43. Wagner, P. D. & Srivastava, S. New paradigms in translational science research in cancer biomarkers. Transl. Res. 159, 343-353 (2012
44. McShane, L. M. et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat. Clin. Pract. Oncol. 2, 416-422 (2005
45. Kelley, R. K. et al. Predictive biomarkers in advance of a companion drug: Ahead of their time? J. Natl Compr. Canc. Netw. 10, 303-309 (2012
46. Parkinson, D. R., Johnson, B. E. & Sledge, G. W. Making personalized cancer medicine a reality: Challenges and opportunities in the development of biomarkers and companion diagnostics. Clin. Cancer Res. 18, 619-624 (2012
47. Ross, J. S. Cancer biomarkers, companion diagnostics and personalized oncology. Biomark. Med. 5, 277-279 (2011
48. Maloney, D. G. et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC C2B8) in patients with recurrent B cell lymphoma. Blood 84, 2457-2466 (1994
49. Younes, A. et al. Brentuximab vedotin (SGN 35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363, 1812-1821 (2010
50. Younes, A., Yasothan, U. & Kirkpatrick, P. Brentuximab vedotin. Nat. Rev. Drug Discov. 11, 19-20 (2011
51. Sok, J. C. et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin. Cancer Res. 12, 5064-5073 (2006
52. Mitsudomi, T. Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer? Lancet Oncol. 12, 710-711 (2011
53. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004
54. De Roock, W. et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304, 1812-1820 (2010
55. Lièvre, A. et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992-3995 (2006
56. Bardelli, A. & Jänne, P. A. The road to resistance: EGFR mutation and cetuximab. Nat. Med. 18, 199-200 (2012
57. Leonard, J. P. et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin. Cancer Res. 10, 5327-5334 (2004
58. FDA. Critical Path Opportunities Report [online], http://www.fda.gov/ downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/UCM077254.pdf (2006
59. FDA. Guidance for Industry. Adaptive Design Clinical Trials for Drugs and Biologics [online], http://www.fda.gov/downloads/ DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf (2010
60. Advani, A. et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B cell non-Hodgkin's lymphoma: Results of a phase I study. J. Clin. Oncol. 28, 2085-2093 (2010
61. Bartlett, N. L. et al. A phase 1 multidose study of SGN 30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 111, 1848-1854 (2008
62. Forero-Torres, A. et al. A phase II study of SGN 30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br. J. Haematol. 146, 171-179 (2009
63. Younes, A. et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J. Clin. Oncol. 30, 2183-2189 (2012
64. Pro, B. et al. Brentuximab vedotin (SGN 35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. J. Clin. Oncol. 30, 2190-2196 (2012
65. Eisenstein, M. Oxford Nanopore announcement sets sequencing sector abuzz. Nat. Biotechnol. 30, 295-296 (2012
66. Foundation Medicine. Cancer diagnostics [online], http://www. foundationmedicine.com/diagnostics.php (2012
67. McCabe, M. T. et al. Mutation of A677 in histone methyltransferase EZH2 in human B cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl Acad. Sci. USA 109, 2989-2994 (2012
68. Ngo, V. N. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115-119 (2011
69. Liu, P. et al. Targeting the phosphoinositide 3 kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627-644 (2009
70. Hans, C. P. et al. Confirmation of the molecular classification of diffuse large B cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103, 275-282 (2004
71. Linton, K. et al. Microarray gene expression analysis of fixed archival tissue permits molecular classification and identification of potential therapeutic targets in diffuse large B cell lymphoma. J. Mol. Diagn. 14, 223-232 (2012
72. Staudt, L. M. Gene expression profiling of lymphoid malignancies. Ann. Rev. Med. 53, 303-318 (2002
73. Kuppers, R. et al. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J. Clin. Invest. 111, 529-537 (2003
74. Staudt, L. M. Molecular diagnosis of the hematologic cancers. N. Engl. J. Med. 348, 1777-1785 (2003
75. Saal, L. H. et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc. Natl Acad. Sci. USA 104, 7564-7569 (2007
76. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01258998 (2012
77. Berry, D. A. Adaptive clinical trials in oncology. Nat. Rev. Clin. Oncol. 9, 199-207 (2011
78. MacReady, N. New report sets guidelines for omics research. Lancet Oncol. 13, e191 (2012
79. Tuma, R. S. Prepping omics for the clinic. J. Natl Cancer Inst. 104, 727-728 (2012
80. Vucic, E. A. et al. Translating cancer 'omics' to improved outcomes. Genome Res. 22, 188-195 (2012
81. Salles, G. et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B cell lymphoma: A study from the Lunenburg Lymphoma Biomarker Consortium. Blood 117, 7070-7078 (2011
82. Andersen, J. N. et al. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci. Transl. Med. 2, 43ra55 (2010
83. Kluk, M. J. et al. Immunohistochemical detection of MYC-driven diffuse large B cell lymphomas. PLoS ONE 7, e33813 (2012
84. Iqbal, J. et al. BCL2 predicts survival in germinal center B cell like diffuse large B cell lymphoma treated with CHOP-like therapy and rituximab. Clin. Cancer Res. 17, 7785-7795 (2011
85. Chabot-Richards, D. S., Martin, D. R., Myers, O. B., Czuchlewski, D. R. & Hunt, K. E. Quantitative image analysis in the assessment of diffuse large B cell lymphoma. Mod. Pathol. 24, 1598-1605 (2011
86. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004
87. van 't veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer.Nature 415, 530-536 (2002
88. Albain, K. S. et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol. 11, 55-65 (2010
89. Kim, C. & Paik, S. Gene-expression-based prognostic assays for breast cancer. Nat. Rev. Clin. Oncol. 7, 340-347 (2010
90. Kirk, R. & Hutchinson, L. Oncology trials - the elephant in the room. Nat. Rev. Clin. Oncol. 9, 185-186 (2012
91. Sharma, M. R. & Schilsky, R. L. Role of randomized phase III trials in an era of effective targeted therapies. Nat. Rev. Clin. Oncol. 9, 208-214 (2011
92. Meurer, W J., Lewis, R. J. & Berry, D. A. Adaptive clinical trials: A partial remedy for the therapeutic misconception? JAMA 307, 2377-2378 (2012
93. Berry, D. A. Adaptive clinical trials: The promise and the caution. J. Clin. Oncol. 29, 606-609 (2011
94. Barker, A. D. et al. I SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86, 97-100 (2009